ARUP Licenses Ipsogen Leukemia MDx IP | GenomeWeb

NEW YORK (GenomeWeb News) – French molecular diagnostics company Ipsogen has licensed rights to use gene variants for diagnosing leukemia to ARUP Laboratories, a reference lab that is part of the University' of Utah's Department of Pathology.

Under the agreement, ARUP licensed non-exclusive rights to use the group of JAK2 gene variations to screen for myeloproliferative neoplasms (MPN), a group of leukemias, in the US, Ipsogen said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.